الفهرس | Only 14 pages are availabe for public view |
Abstract Many patients, particularly children and the elderly population find it inconvenient to ingest conventional solid dosage forms such as tablets and capsules due to an impaired ability to swallow. This leads to patient non-compliance and potentially prolonged duration of treatment. This issue can be addressed through the development of orally disintegrating dosage forms that disperse or dissolve in the saliva and are swallowed without water. Besides improving the acceptability and compliance of patients, FDTs have been investigated for their potential to increase the bioavailability through the enhancement of the dissolution rate. Additionally, pharmaceutical companies have another reason for the development of FDTs. At the end of the patent term of a drug, development of a new dosage form provides a life cycle extension of the product (Rahman, Zidan et al. 2010) |